Discovery of gene locus associated with cardiovascular disease raises hope of new treatments

An international team of researchers has discovered a gene locus that could help the development of new drugs to fight cardiovascular disease (CVD). The locus is associated with low-density lipoprotein (LDL) cholesterol, which plays a causal role in the development of diseases of the cardiovascular system.

Analysing genetic data from nearly 12,000 participants across five surveys in a genome-wide association study were scientists from the UK, Finland, the USA, Switzerland, Australia and Canada. They were able to pinpoint an association between LDL-cholesterol and a specific chromosome region, a locus that had not previously been liked to lipid metabolism. Two of the scientists received financial support as part of the EU DIABESITY project.

"The results potentially provide insight into the biological mechanisms that underlie the regulation of LDL cholesterol and might help in the discovery of novel therapeutic targets for cardiovascular disease, the scientists report in the current issue of the peer-reviewed journal The Lancet. Previous studies have shown that patients benefit from reducing LDL-cholesterol levels in the blood.

While the findings of the present study are corroborated by others, Dr Ronald Krauss of the Children's Hospital Oakland Research Institute, Oakland, USA, points out in a comment accompanying the paper that there is still more work to be done: "In addition to the identification of new treatment targets, the discovery of genetic polymorphisms that affect LDL and other markers of cardiovascular disease risk could provide a means to categorise specific phenotypes that might merit different treatments and to identify at-risk individuals."

"These polymorphisms probably include a high proportion of regulatory variants that would be of particular clinical interest because of the potential for modulation by preventive or therapeutic measures," Dr Krauss adds. "Overall, to discover further genetic effects on LDL cholesterol, additional candidate genes must be identified from studies of biological pathways or clinical cases, or genome-wide searches will be needed in even larger and more diverse populations, with more complete genotyping or resequencing and with acquisition of potentially relevant environmental information."

Diseases of the heart and circulatory system are the main cause of death in the European Union, accounting for over 1.9 million deaths each year. According to the British Heart Foundation Statistics Website, 42% of all deaths in the EU (46% deaths in women and 39% deaths in men) are caused by CVD - slightly less than for Europe as a whole (49%). Between one-third and a half of deaths from CVD stem from coronary heart disease, and around a quarter from a stroke.

For further information, please visit:
http://www.eurodiabesity.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...